MedTrace Logo

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

NCT07043946 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-27

No results posted yet for this study

Summary

The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Conditions

  • Immune Thrombocytopenia (ITP)
  • ITP
  • Biologics
  • Monoclonal
  • Anti-CD19

Interventions

DRUG

Budoprutug

Single IV dose of study product on Day 1 and Day 15

Sponsors & Collaborators

  • Climb Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Climb Bio, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-30
Primary Completion
2027-08-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • Bulgaria
  • Greece
  • Serbia
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07043946 on ClinicalTrials.gov